Log In
BCIQ
Print this Print this
 

ALT-P7

  Manage Alerts
Collapse Summary General Information
Company Alteogen Inc.
DescriptionAntibody-drug conjugate inhibitor of epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2; neu)
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionAntibody-drug conjugate; Epidermal growth factor (EGF) receptor 2 (HER2) (ErbB2) (neu) inhibitor
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPreclinical
Standard IndicationBreast cancer
Indication DetailsBreast cancer
Regulatory Designation
Partner3SBio Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/12/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today